Insider buying last 90 days
No open-market insider purchases were filed for BLLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BLLN insider filing, plotted on the chart in Gekko.Open BLLN in Gekko
NASDAQ: BLLN
BillionToOne (BLLN) Stock Analysis & Forecast
Sep 28 close
$121.72−1.36 (−1.1%)
Gekko Brief
AI summaryThis week's news around BillionToOne centers on insider selling, with multiple Form 144 filings and executed sales by SVP of Laboratory Operations John Roderick ten Bosch, General Counsel Thomas P. Lynch, and insider David Tsao, several under pre-arranged Rule 10b5-1 trading plans. Separately, a regulatory development is in view: the Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, a change flagged as affecting BillionToOne and CareDx differently.
BLLN closed at $121.72, down 1.1% on the day, with the stock trading above both its 50-day average of $109.17 and 200-day average of $95.01. The one-month return stands at 27.9% and the six-month return at 75%. The GekkoIndex reads 47.6, placing the stock in the Neutral zone, down 8.1 points over the last five sessions. Fair value sits at $176.42, putting the current price 31% below that mark.
Earnings are scheduled for 6 October 2026, seven days away and inside a typical 20-trading-day holding window, following a first-quarter report in which revenue grew 84% year over year and EPS of $0.34 beat the $0.03 estimate, producing a 16.3% reaction. The average absolute reaction across the last four quarters has been 10.4%, with three beats out of four. Analyst coverage from 7 firms shows 6 buy ratings and 1 hold, with a consensus target of $119.75, implying a consensus downside of 1.6%.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
BillionToOne price vs fair value
Close $121.72200-day averageGekko Fair Value $176.42
BillionToOne quick facts
- Market cap
- $5.60B
- P/E ratio
- 162.2
- Forward P/E
- 69.9
- EPS, TTM
- $0.77
- Revenue, TTM
- $397.4M
- Profit margin
- 8.4%
- Dividend yield
- —
- Beta
- —
- Volume
- 343,635 avg 633,795
- 1-year return
- —
- Typical daily move
- ±5.5%
- Typical 20-day move
- ±14.4%
- 50-day average
- $109.17
- 200-day average
- $95.01
- Next earnings
- Oct 6
- Shares outstanding
- 42.64M
BillionToOne swing-trade checklist
BillionToOne scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $121.72 is above the 50-day ($109.17) and 200-day ($95.01) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
47.6, Neutral
Reading 47.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
31.0% below
Price is 31% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 7 days
Reports on Oct 6, 2026, 7 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
BillionToOne stock chart and price history
BillionToOne closed at $121.72 on Sep 28, 2026, inside a 52-week range of $61.96 to $150.44.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +27.9%
- 3 months
- +1.1%
- 6 months
- +75.0%
The full BLLN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLLN in Gekko
Follow BillionToOne through every session
Put BLLN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BLLN in GekkoFree for 7 days. No credit card required.
About BillionToOne
BillionToOne builds molecular diagnostic tests around a platform that counts single strands of DNA, aiming to sharpen how accurately diseases can be detected. Rather than relying on broader estimates, the company's approach focuses on isolating and tallying individual molecules, which underlies its work in prenatal and cancer testing.
Among its offerings is UNITY Complete, a screening test that uses a blood draw from an expectant mother to gauge a fetus's chances of aneuploidies, recessive genetic disorders, and fetal antigen issues without any invasive procedure. On the oncology side, Northstar Select analyzes a patient's blood to detect tumor-related mutations, including deletions, insertions, and single-point changes, while Northstar Response follows how a cancer evolves over time by examining methylation patterns. These tools are aimed at supporting both expectant parents and cancer patients through ongoing clinical monitoring.
Founded in 2016, BillionToOne runs its operations out of Menlo Park, California. The company trades on the NASDAQ exchange under the ticker symbol BLLN.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- billiontoone.com
BillionToOne GekkoIndex: the smart money zone
BillionToOne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.6, in the Neutral zone, down 8.1 points over five sessions.
47.6Neutral
Down 8.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 12 | +9.2% | +5.2% | ||
| Accumulation | 89 | +2.8% | +3.9% | ||
| Neutral (current zone) | 106 | −0.8% | −0.4% | ||
| Distribution | 10 | −6.0% | −2.9% | ||
| Selling | 0 | Not available | |||
Average BLLN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BLLN price, zone by zone.Track BLLN in Gekko
Is BillionToOne stock overvalued? Gekko Fair Value
BillionToOne trades 31.0% below Gekko Fair Value of $176.42, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BillionToOne shares are worth, recalculated every trading day.
$176.42
Gekko Fair Value, Sep 26, 2026
31.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BLLN in Gekko
BillionToOne insider and Congress trading
No open-market insider purchases were filed for BillionToOne, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BLLN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BLLN, plotted on the chart in Gekko.Open BLLN in Gekko
Buybacks
BillionToOne has been buying back its own shares.
- Bought back, year ended Dec 31, 2024
- $546K
- As a share of market cap
- 0.01%
From company filings.
BillionToOne earnings: next date and track record
BillionToOne reports on Oct 6, 2026 (7 days away), and beat the EPS estimate in 3 of its last 4 reports.
Next earnings report
Oct 6, 2026
7 days away
- EPS estimate
- $0.16
- Revenue estimate
- $116.1M
3 of 4reports beat the EPS estimate
±10.4%average move across the report
1 of 4reports followed by a gain
Share-price move across each report
Last earnings call, May 6, 2026 AI summary
- What they said
- BillionToOne reported Q1 2026 revenue growth of 84% YoY with test volume up 44% YoY. ASP increased 28% YoY to $571/test while COGS held at $153/test, driving gross margins to 73% (up 9pp YoY). The company achieved a 16% GAAP operating margin and 24% adjusted EBITDA margin, ending Q1 with $537.5M cash. Contracted lives reached 300 million following an Anthem agreement.
- Guidance
- Management reaffirmed its long-term goal of S&P 500 inclusion and category-defining growth. Tumor-naive MRD oncology product is on track to launch by year-end 2026. Response coverage MolDX comments have been addressed, with reimbursement progress ongoing.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | $0.34 est $0.03 | $108.4M est $97.14M | +16.3% |
| Mar 4, 2026 | $0.11 est $0.06 | $96.05M est $87.19M | −13.2% |
| Dec 10, 2025 | $0.91 est $0.16 | $83.52M est $82.90M | −11.0% |
| Dec 9, 2025 | $0.10 est $0.14 | $83.52M est $82.90M | −0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BillionToOne stock forecast and analyst price targets
Analysts’ average 12-month price target for BillionToOne is $119.75, −1.6% from the last close, from 7 firms rating the stock in the last 90 days.
$119.75consensus 12-month target, −1.6% from the last close
Now $121.72Avg $119.75
Low $90High $145
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 2 | Canaccord Genuity | $120 | −1.4% |
| Aug 6 | William Blair | — | — |
| Aug 6 | Stifel Nicolaus | $145 | +19.1% |
| Aug 6 | J.P. Morgan | $130 | +6.8% |
| Aug 6 | Wells Fargo | $90 | −26.1% |
−0.4%average 20-day move after past Neutral readings
±5.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BillionToOne market cap and key statistics
BillionToOne’s market cap is $5.60B, with a P/E ratio of 162.2 and revenue of $397.4M over the last twelve months.
Valuation
- Market cap
- $5.60B
- P/E ratio
- 162.2
- Forward P/E
- 69.9
- EPS, TTM
- $0.77
- Gekko Fair Value
- $176.42
Trading
- Volume
- 343,635
- Avg volume, 20 days
- 633,795
- 52-week high
- $150.44
- 52-week low
- $61.96
- Shares outstanding
- 42.64M
Financials
- Revenue, TTM
- $397.4M
- Profit margin
- 8.4%
- Return on equity
- 10.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±5.5%
- Typical 20-day move
- ±14.4%
BillionToOne stock news this week
Coverage of BillionToOne this week reads negative: 0 positive, 3 neutral and 3 negative headlines.
- Pre-IPO shares valued at $169,920 are proposed for sale by a BillionToOne (BLLN) officer.Stock Titan, Sep 25
- David Tsao proposes a $416,625 share sale in BillionToOne (BLLN) after earlier sales.Stock Titan, Sep 24
- BillionToOne SVP John ten Bosch sells $150,959 of class A common stockInvesting.com, Sep 24
- Under a trading plan, BillionToOne (BLLN) lab operations SVP sold 1,416 shares; 23,635 remain.Stock Titan, Sep 24
- Medicare Lab Fee Changes Impact BillionToOne, CareDx DifferentlyBenzinga, Sep 23
- BillionToOne (BLLN) legal chief sells 35K shares under preset trading planStock Titan, Sep 22
BillionToOne peers
BillionToOne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| GHGuardant Health | Neutral | 0.5% above |
| SOLVSolventum | Neutral | 16.4% below |
| EHCEncompass Health | Neutral | 7.6% above |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
A peer links to its own page where one exists.
BillionToOne stock FAQ
What is BillionToOne’s market cap?
BillionToOne’s market cap is $5.60B at the Sep 28, 2026 close of $121.72, with 42.64M shares outstanding. The shares trade on a P/E ratio of 162.2.
What is the BillionToOne stock forecast?
The consensus analyst 12-month price target for BillionToOne is $119.75, −1.6% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BillionToOne stock overvalued or undervalued?
On Gekko’s estimate BillionToOne is undervalued: the Sep 28, 2026 close of $121.72 is 31.0% below Gekko Fair Value of $176.42. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BillionToOne report earnings next?
BillionToOne is expected to report on Oct 6, 2026 (7 days away). Analysts expect earnings of $0.16 per share on revenue of $116.1M. BillionToOne beat the earnings estimate in 3 of its last 4 reports, moving 10.4% on average across the report.
What is BillionToOne’s 52-week high and low?
BillionToOne’s 52-week high is $150.44 and its 52-week low is $61.96; it closed at $121.72 on Sep 28, 2026.
Is BillionToOne stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BillionToOne the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.